KRAS and non-small cell lung carcinoma: Similarly, co‐clinical trials in GEMMs of NSCLC showed that Kras/Lkb1‐mutant lung tumors are more resistant to combination therapy with docetaxel and the MEK inhibitor selumetinib than Kras‐ or Kras/p53‐mutant tumors, highlighting LKB1 as a potential determinant of resistance in clinical trials with this combination therapy (Chen et al, 2012).